(-)-Epicatechin dosing in normal and overweight / obese subjects showed a 30% reduction in C-reactive protein, a key marker of inflammation in the body

Published November 2016

This randomized, placebo-controlled, and double-blind study was conducted on 30 human subjects with high triglyceride levels for 4 weeks.

A precise formulation and dosage of (-)-epicatechin was administered to the treated group.

Note that the formulation and dosage of (-)-epicatechin used in this clinical are relevant to our key ingredient, Mitokatylst™ in the product Mitokatylst™ – E.

Blood samples were collected in all subjects to assess indicators of glucose and lipid control as well as inflammation.

Key Takeaways

A significant reduction of the levels of high-sensitivity C-reactive protein (hs-CRP) was noted (-30.2% in the treated group) while the placebo group did not show any change in their hs-CRP levels. The hs-CRP test is used to estimate inflammation in the body and can help predict the risk of heart disease and stroke.
Test results for the treated subjects showed significant decreases in triglycerides (-30%) versus the placebo group (-12.9%). The group receiving (-)-epicatechin also showed a 25.8% reduction in their TG/HDLc index whereas the placebo group showed a 5.7% reduction.
Test results also demonstrated significant decreases in fructosamine blood levels suggesting improved blood glucose control.
The effects of (-)-epicatechin appeared more prominent in the overweight subjects.

READ PAPER

Authors Gabriela Gutiérrez-Salmeán, Eduardo Meaney, Miguel A. Lanaspa, Christina Cicerchi, Richard J. Johnson, Sundeep Dugar, Pam Taub, Israel Ramírez-Sánchez, Francisco Villarreal, George Schreiner, Guillermo Ceballos